INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,470,678 | -2.1% | 46,511 | +26.2% | 0.01% | 0.0% |
| Q2 2023 | $1,502,865 | +125347.8% | 36,853 | +14.6% | 0.01% | +20.0% |
| Q1 2023 | $1,198 | +47.0% | 32,149 | +37.6% | 0.01% | +25.0% |
| Q4 2022 | $815 | -100.0% | 23,361 | -23.4% | 0.00% | -55.6% |
| Q3 2022 | $1,705,000 | +46.2% | 30,490 | +35.3% | 0.01% | +50.0% |
| Q2 2022 | $1,166,000 | -26.7% | 22,532 | +2.9% | 0.01% | -25.0% |
| Q1 2022 | $1,590,000 | -10.8% | 21,890 | +45.2% | 0.01% | 0.0% |
| Q4 2021 | $1,782,000 | +289.9% | 15,076 | +342.5% | 0.01% | +300.0% |
| Q3 2021 | $457,000 | +319.3% | 3,407 | +401.0% | 0.00% | +100.0% |
| Q2 2021 | $109,000 | +118.0% | 680 | +8.6% | 0.00% | – |
| Q1 2021 | $50,000 | +150.0% | 626 | +67.8% | 0.00% | – |
| Q4 2020 | $20,000 | +233.3% | 373 | +14.8% | 0.00% | – |
| Q3 2020 | $6,000 | – | 325 | +4542.9% | 0.00% | – |
| Q4 2019 | $0 | – | 7 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |